<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RIVASTIGMINE TARTRATE</span><br/>(ri-vas'tig-meen)<br/><span class="topboxtradename">Exelon<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">cholinergic (parasympathomimetic)</span>; <span class="classification">cholinesterase inhibitor</span><br/><b>Prototype: </b>Neostigmine Bromide<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL solution</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits acetylcholinesterase G<sub>1</sub> form of this enzyme.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The G<sub>1</sub> form of acetylcholinesterase is found in higher levels in the brains of patients with Alzheimer's disease. Rivastigmine inhibits
         acetylcholinesterase more specifically in the brain (hippocampus and cortex) than the heart or skeletal muscle.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of mild to moderate dementia of the Alzheimer's type.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to rivastigmine or carbamate derivatives; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of toxicity to cholinesterase inhibitors (e.g. tacrine); diabetes mellitus, cardiovascular/pulmonary disease; GI disorders
         including intestinal obstruction/peptic ulcer disease; concurrent use of other cholinergic agents, or anticholinergic agents;
         urogenital tract obstruction; Parkinson disease; pregnancy (category B); hepatic or renal insufficiency; concurrent use of
         NSAIDs.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Alzheimer's Dementia</span><br/><span class="rdage">Adult/</span><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 1.5 mg b.i.d with food, may increase by 1.5 mg b.i.d. q 2 wks if tolerated, target dose 36 mg b.i.d. (max:
               12 mg b.i.d.) (if discontinued for a few doses, restart at <img src="../images/special/lesserorequal.gif"/> last dose, if
               treatment is interrupted for several days, reinitiate with 1.5 mg b.i.d. and titrate q2wk as above)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give both capsules and liquid with food.</li>
<li>Give liquid form undiluted or mixed with water, juice, or soda (do not mix with other liquids). Stir completely to dissolve.
            Ensure that entire mixture is swallowed.
         </li>
<li>Discontinue drug for several days if significant anorexia, nausea, or vomiting occur. When adverse effects subside, restart
            at same or lower dose level (see <small>ROUTE &amp; DOSAGE</small>).
         </li>
<li>Store capsules and oral solution below 25° C (77° F). Ensure that bottle of liquid is in an <small>UPRIGHT</small> position.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, increased sweating, syncope, fatigue, malaise, flu-like syndrome. <span class="typehead">CV:</span> Hypertension. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, anorexia</span>, dyspepsia, <span class="speceff-common">diarrhea, abdominal pain</span>, constipation, flatulence, eructation. <span class="typehead">Metabolic:</span> Weight loss. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, headache</span>, somnolence, tremor, insomnia, confusion, depression, anxiety, hallucination, aggressive reaction. <span class="typehead">Respiratory:</span> Rhinitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May exaggerate muscle relations with <b>succinylcholine</b> and other <span class="classification">neuromuscular blocking agents</span>, may attenuate effects of <span class="classification">anticholinergic agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed, 40% reaches systemic circulation. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Duration:</span> 10 h. <span class="typehead"> Distribution:</span>  Crosses blood-brain barrier with CSF peak concentrations in 1.42.6 h, 40% protein bound. <span class="typehead">Metabolism:</span> Metabolized by cholinesterase-mediated hydrolysis. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cognitive function and ability to perform ADLs.</li>
<li>Monitor for and report S&amp;S of GI distress: Anorexia, weight loss, nausea and vomiting.</li>
<li>Lab tests: Periodic ECG, serum electrolytes, Hgb &amp; Hct, urinalysis, blood glucose HbA<sub>1C</sub>, especially with long-term therapy.
         </li>
<li>Monitor ambulation as dizziness is a common adverse effect.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Review instruction sheet provided with liquid form of the drug.</li>
<li>Monitor weight at least weekly.</li>
<li>Report any of the following to the physician: Loss of appetite, weight loss, significant nausea and/or vomiting.</li>
<li>Supervise activity since there is a high potential for dizziness.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>